Weight loss alone does not explain lower heart disease for those on semaglutide

Note to editors

F unding : Novo Nordisk

D isclosures : Helen M. Colhoun declares serving on advisory panels for Novo Nordisk, Roche and Bayer; receiving research funding from Sanofi, Roche, and IQVIA, and grants from Chief Scientist

Office, Diabetes UK, European Commission, Juvenile Diabetes Research Foundation, and Medical Research Council; and holding stock in Roche Pharmaceuticals and Eli Lilly. A. Michael Lincoff declares having received honoraria from Akebia, Alnylam, Amgen, Ardelyx, Becton Dickson, Brainstorm Cell, Eli Lilly, Endologix, FibroGen, GlaxoSmithKline, Intarcia, Medtronic, Neovasc, Novo Nordisk, Provention Bio, and ReCor, and for consulting activities and research funding to his institution from AbbVie, AstraZeneca, CSL Behring, Eli Lilly,

Esperion, and Novartis. Donna Ryan declares having received consulting honoraria from Altimmune, Amgen, Biohaven, Boehringer Ingelheim, Calibrate, Carmot Therapeutics, CinRx, Eli Lilly, Epitomee, Gila Therapeutics, Ifa Celtic, Novo Nordisk, Pfizer, Rhythm, Scientific Intake, Wondr Health, and Zealand, and stock options

from Calibrate, Epitomee, Scientific Intake and Xeno Bioscience. Ildiko Lingvay declares having received research grants from Boehringer Ingelheim, Merck, Mylan Pharmaceuticals Inc., Novo Nordisk, Pfizer, and Sanofi US Services Inc.; she has served as a consultant for AstraZeneca, Bayer Healthcare Pharmaceuticals

Inc., Biomea, Boehringer Ingelheim, Carmot, Eli Lilly and Company, Intarcia, Intercept Pharmaceuticals, Inc., Janssen Global Services, LLC, Johnson & Johnson Medical Devices & Diagnostics Group - Latin America, L.L.C., MannKind Corporation, Merck, Novo Nordisk, Pfizer Inc., Sanofi US Services Inc., Shionogi Inc., Structure Therapeutics, Target Pharma, Valeritas, Inc., and Zealand Pharma; and has received travel expenses from Boehringer Ingelheim, Eli Lilly and Company, Johnson & Johnson Medical Devices & Diagnostics Group - Latin

America, L.L.C., Novo Nordisk, Sanofi US Services Inc., and Zealand Pharma A/S. Steven E. Kahn, for the period over which SELECT was conducted, declares receiving advisory board/consulting fees from AltPep, Bayer, Boehringer Ingelheim, Casma Therapeutics, Eli Lilly, Intarcia, Merck, Novo Nordisk, Oramed, Pfizer, and Third Rock Ventures. G. Kees Hovingh declares being an employee of and stakeholder in Novo Nordisk. Søren Hardt-Lindberg declares being an employee of and stakeholder in Novo Nordisk. Tugce Kalayci Oral declares being an employee of and stakeholder in Novo Nordisk. Peter E. Weeke declares being an employee of and stakeholder

in Novo Nordisk. Martin Linder declares being an employee of and stakeholder in Novo Nordisk. Ales Linhart has received speakers' fees and consultancy honoraria from Alnylam, Avrobio, Chiesi, Novo Nordisk, Sanofi-Genzyme, and Takeda. Bartolome Burguera has received honoraria related to participation on this trial, and has no financial conflicts related to this publication. André P. van Beek declares being contracted via the

University of Groningen (no personal payment) to undertake consultancy for Novo Nordisk, Eli Lilly, and Boehringer Ingelheim. Jose Francisco Kerr Saraiva declares having received consulting honoraria from Amgen, Boehringer Ingelheim, Merck Sharp & Dohme, Novartis, Novo Nordisk, Bayer, Lilly, Hypera, Servier, Medtronic, and Astra Zeneca. Yaron Arbel declares having received honoraria from Medtronic, Novo Nordisk, Sanofi, Amgen, and Novartis. In addition, he has received honoraria related to participation in this trial.Scott S. Emmerson declares having received consulting honoraria from Amylyx, AstraZeneca, Avillion, Ayala, Bayer,

BeiGene, Boehringer Ingelheim, 89 Bio, BioAge, BioAtla, Bristol Meyers Squibb, BridgeBio, Daiichi Sankyo, Denovo, Fore Therapeutics, GlaxoSmithKline, Inovio, Insmed, Ipsen, Karuna, Lilly, Lundbeck, Mirati, Moderna, Novartis, Novavax, Novo Nordisk, NSABP, Pfizer, Principia, Reata, Rebiotx, Roche, Sanofi, SOLVD, Sutro Biopharma, and TG Therapeutics. Jorge Plutzky declares having received consulting honoraria from Altimmune, Amgen, Esperion Therapeutics, Inc., Merck, MJH Life Sciences, Novartis, and Novo Nordisk; he has received

a grant, paid to his institution, from Boehringer Ingelheim, and holds the position of Director, Preventive Cardiology, at Brigham and Women's Hospital. John Deanfield declares having received consulting honoraria

from Amgen, Boehringer Ingelheim, Merck, Pfizer, Aegerion, Novartis, Sanofi, Takeda, Novo Nordisk, and Bayer, and research grants from British Heart Foundation, MRC (UK), NIHR, PHE, MSD, Pfizer, Aegerion, Colgate, and Roche.

The European Heart Journal is the flagship journal of the European Society of Cardiology. It is published on behalf of the ESC by Oxford Journals, a division of Oxford University Press.